Relmada Therapeutics (RLMD) Assets Average (2013 - 2026)
Relmada Therapeutics (RLMD) reported Assets Average of $164.7 million for Q1 2026, up 348.13% year-over-year from $36.7 million in Q1 2025, and up 202.5% on a QoQ basis from $54.4 million in Q4 2025.
Relmada Therapeutics (RLMD) has 14 years of Assets Average data on file, last reported at $164.7 million in Q1 2026.
- Quarterly Assets Average rose 348.13% year-over-year to $164.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.7 million (up 348.13% YoY) and the FY2025 annual result came in at $69.9 million, down 2.48% from the prior year.
- Assets Average climbed to $164.7 million in Q1 2026 per RLMD's latest filing, from $54.4 million in the prior quarter.
- Across five years, Assets Average topped out at $224.6 million in Q1 2022 and bottomed at $18.0 million in Q3 2025.
- The 5-year median for Assets Average is $103.4 million (2023), against an average of $111.2 million.
- The widest annual swing landed in 2025, when Assets Average slumped 71.6%; it then soared 348.13% in 2026.
- Tracing RLMD's Assets Average over 5 years: stood at $170.0 million in 2022, then slumped by 39.21% to $103.4 million in 2023, then tumbled by 50.87% to $50.8 million in 2024, then rose by 7.23% to $54.4 million in 2025, then jumped by 202.5% to $164.7 million in 2026.
- Per Business Quant, the three latest RLMD Assets Average figures stand at $164.7 million (Q1 2026), $54.4 million (Q4 2025), and $18.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 164.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 164.68 Mn |
| Dec 31, 2025 | 54.44 Mn |
| Sep 30, 2025 | 18.00 Mn |
| Jun 30, 2025 | 24.40 Mn |
| Mar 31, 2025 | 36.75 Mn |
| Dec 31, 2024 | 50.77 Mn |
| Sep 30, 2024 | 63.38 Mn |
| Jun 30, 2024 | 77.72 Mn |
| Mar 31, 2024 | 90.98 Mn |
| Dec 31, 2023 | 103.35 Mn |
| Sep 30, 2023 | 115.59 Mn |
| Jun 30, 2023 | 128.80 Mn |
| Mar 31, 2023 | 144.24 Mn |
| Dec 31, 2022 | 170.01 Mn |
| Sep 30, 2022 | 201.45 Mn |
| Jun 30, 2022 | 220.79 Mn |
| Mar 31, 2022 | 224.57 Mn |
| Dec 31, 2021 | 157.13 Mn |
| Sep 30, 2021 | 100.85 Mn |
| Jun 30, 2021 | 107.32 Mn |
| Mar 31, 2021 | 111.03 Mn |
| Dec 31, 2020 | 121.89 Mn |
| Sep 30, 2020 | 130.08 Mn |
| Jun 30, 2020 | 124.99 Mn |
| Mar 31, 2020 | 116.28 Mn |
| Dec 31, 2019 | 62.83 Mn |
| Sep 30, 2019 | 9.37 Mn |
| Jun 30, 2019 | 6.41 Mn |
| Mar 31, 2019 | 2.95 Mn |
| Dec 31, 2018 | 2.43 Mn |
| Sep 30, 2018 | 2.30 Mn |
| Jun 30, 2018 | 3.92 Mn |
| Mar 31, 2018 | 5.68 Mn |
| Dec 31, 2017 | 6.09 Mn |
| Sep 30, 2017 | 4.23 Mn |
| Jun 30, 2017 | 3.50 Mn |
| Mar 31, 2017 | 5.20 Mn |
| Dec 31, 2016 | 7.07 Mn |
| Sep 30, 2016 | 9.08 Mn |
| Jun 30, 2016 | 11.48 Mn |
| Mar 31, 2016 | 14.66 Mn |
| Dec 31, 2015 | 18.54 Mn |
| Sep 30, 2015 | 22.44 Mn |
| Jun 30, 2015 | 26.12 Mn |
| Mar 31, 2015 | 30.32 Mn |
| Dec 31, 2014 | 30.32 Mn |
| Sep 30, 2014 | 26.81 Mn |
| Nov 30, 2013 | 16,154.50 |
| Aug 31, 2013 | 12,371.00 |
| May 31, 2013 | 7,463.50 |